Drug intelligence / Profile preview

CAR-T EpCAM

Development stage: Unknown
Lead developer: Shanghai Tenth People's Hospital
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

CAR-T EpCAM is an autologous chimeric antigen receptor (CAR) T-cell therapy targeting the Epithelial Cell Adhesion Molecule (EpCAM), a transmembrane glycoprotein frequently overexpressed in various carcinomas. Developed by Shanghai 10th People's Hospital, this cell therapy involves the genetic modification of a patient's own T cells to express a CAR that recognizes EpCAM-positive tumor cells, leading to targeted cell lysis. It is currently being evaluated in clinical trials for the treatment of recurrent or refractory solid tumors, including gastric, esophageal, lung, colorectal, and ovarian cancers, as well as mesothelioma.

Other names: EpCAM-specific CAR-T cellsanti-EpCAM CAR-T

Targets

EPCAM (Epithelial cell adhesion molecule)

Beyond the preview

Go deeper on CAR-T EpCAM.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CAR-T EpCAM.

Explore the full profile